Mavacamten

Last updated

Mavacamten
Mavacamten.svg
Clinical data
Trade names Camzyos
Other namesMYK-461
AHFS/Drugs.com Monograph
MedlinePlus a622047
License data
Pregnancy
category
Routes of
administration 		By mouth
Drug class Cardiac myosin inhibitor
ATC code
Legal status
Legal status
Identifiers
  • 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
CAS Number
PubChem CID
DrugBank
UNII
KEGG
Chemical and physical data
Formula C15H19N3O2
Molar mass 273.336 g·mol−1
3D model (JSmol)
  • CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
  • InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
  • Key:RLCLASQCAPXVLM-NSHDSACASA-N

Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy. [6] [7]

Contents

Mavacamten is a small-molecule allosteric [8] and cardiac myosin inhibitor. [6] It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb. [9] In clinical studies, mavacamten has demonstrated significant efficacy in reducing cardiac muscle contractility by targeting the sarcomere hypercontractility that is one of the characteristics of hypertrophic cardiomyopathy and inhibits excessive myosin actin cross-bridge formation, shifting the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. [6]

Mavacamten was approved for medical use in the United States in April 2022. [6] [10] [11] [12] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [13]

Medical uses

Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. [6]

Adverse effects

The US prescribing information for mavacamten contains a boxed warning regarding heart failure. Mavacamten reduces LVEF and can cause heart failure due to systolic dysfunction. [6]

History

Mavacamten was granted orphan drug designation by the US Food and Drug Administration (FDA). [14]

Society and culture

On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camzyos, intended for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). [15] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG. [15] In June 2023, the European Commission approved Mavacamten. [7] [16] [17]

Mavacamten is approved for use in the US, [18] Canada, [19] Australia, [20] South Korea, [21] Singapore, [22] Switzerland, [23] Brazil [24] and Macau. [25]

Names

Mavacamten is the international nonproprietary name (INN). [26]

Related Research Articles

ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles. This results in the heart being less able to pump blood effectively and also may cause electrical conduction problems.

<span class="mw-page-title-main">Disopyramide</span> Chemical compound

Disopyramide is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity.

<span class="mw-page-title-main">Dasatinib</span> Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

<span class="mw-page-title-main">Saxagliptin</span> Chemical compound

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.

Alcohol septal ablation (ASA) is a minimally invasive heart procedure to treat hypertrophic cardiomyopathy (HCM).

Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.

<span class="mw-page-title-main">Roflumilast</span> Medication

Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).

<span class="mw-page-title-main">Apixaban</span> Anticoagulant medication

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

<span class="mw-page-title-main">Nivolumab</span> Cancer drug

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

<span class="mw-page-title-main">Peter R. Kowey</span> American cardiologist and medical researcher

Peter R. Kowey is an American cardiologist and medical researcher. He is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College of Thomas Jefferson University and holds the William Wikoff Smith Chair in Cardiovascular Research at Lankenau Institute for Medical Research.

<span class="mw-page-title-main">Ozanimod</span> Medication

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

<span class="mw-page-title-main">Cytokinetics</span> California-based publicly traded biopharmaceutical company

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activatorsand muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat large B-cell lymphoma.

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.

Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma.

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion.

<span class="mw-page-title-main">Deucravacitinib</span> Chemical compound

Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.

References

  1. 1 2 "Camzyos". Therapeutic Goods Administration (TGA). 13 October 2022. Archived from the original on 5 February 2023. Retrieved 28 April 2023.
  2. ↑ "Camzyos (Bristol-Myers Squibb Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 13 November 2022. Retrieved 28 April 2023.
  3. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ↑ "Camzyos Product information". Health Canada . Archived from the original on 3 January 2023. Retrieved 2 January 2023.
  5. ↑ "Summary Basis of Decision for Camzyos". Health Canada . 12 April 2023. Archived from the original on 3 August 2023. Retrieved 5 June 2023.
  6. 1 2 3 4 5 6 7 "Camzyos- mavacamten capsule, gelatin coated". DailyMed . 28 April 2022. Archived from the original on 3 July 2022. Retrieved 15 May 2022.
  7. 1 2 3 "Camzyos EPAR". European Medicines Agency (EMA). 24 July 2023. Archived from the original on 3 August 2023. Retrieved 2 August 2023.
  8. ↑ Edelberg JM, Sehnert AJ, Mealiffe ME, Del Rio CL, McDowell R (September 2022). "The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review". American Journal of Cardiovascular Drugs. 22 (5): 497–510. doi:10.1007/s40256-022-00532-x. PMC   9467968 . PMID   35435607.
  9. ↑ "Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise" (Press release). Bristol Myers Squibb. 17 November 2020. Archived from the original on 29 April 2022. Retrieved 29 April 2022– via Business Wire.
  10. ↑ "FDA approves new drug to improve heart function in adults with rare heart condition" (Press release). U.S. Food and Drug Administration (FDA). 29 April 2022. Archived from the original on 29 November 2022. Retrieved 29 November 2022.
  11. ↑ "FDA approves Bristol Myers' oral heart disease drug". Reuters. 29 April 2022. Archived from the original on 29 November 2022. Retrieved 29 November 2022.
  12. ↑ "U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms" (Press release). Bristol Myers Squibb. 28 April 2022. Archived from the original on 29 April 2022. Retrieved 29 April 2022– via Business Wire.
  13. ↑ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  14. ↑ "Mavacamten Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 27 April 2016. Archived from the original on 3 July 2022. Retrieved 29 April 2022.
  15. 1 2 "Camzyos: Pending EC decision". European Medicines Agency (EMA). 26 April 2023. Archived from the original on 29 April 2023. Retrieved 27 April 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. ↑ "Camzyos". Union Register of medicinal products. 27 June 2023. Archived from the original on 3 August 2023. Retrieved 2 August 2023.
  17. ↑ Priyan, Vishnu (27 June 2023). "EC approves BMS' Camzyos for hypertrophic cardiomyopathy". Pharmaceutical Technology. Archived from the original on 27 June 2023. Retrieved 27 June 2023.
  18. ↑ "FDA approves new drug to improve heart function in adults with rare heart condition". U.S. Food and Drug Administration (FDA). 29 April 2022. Archived from the original on 29 November 2022. Retrieved 29 November 2022.
  19. ↑ "Health Canada Approves Camzyos (mavacamten capsules) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy". Bristol Myers Squibb (Press release). 10 November 2022. Retrieved 27 June 2023.
  20. ↑ "Camzyos". Therapeutic Goods Administration (TGA). 13 October 2022. Archived from the original on 5 February 2023. Retrieved 28 June 2023.
  21. ↑ "의약품안전나라". Ministry of Food and Drug Safety (in Korean). Archived from the original on 2 July 2023. Retrieved 27 June 2023.
  22. ↑ "LianBio Announces Marketing Approval of Camzyos (mavacamten) in Singapore". BioSpace. Archived from the original on 27 June 2023. Retrieved 27 June 2023.
  23. ↑ "Camzyos, Hartkapseln (Mavacamtenum)". Swissmedic . Archived from the original on 27 June 2023. Retrieved 27 June 2023.
  24. ↑ "Camzyos (mavacanteno): novo registro". Agência Nacional de Vigilância Sanitária - Anvisa (in Brazilian Portuguese). Archived from the original on 27 June 2023. Retrieved 27 June 2023.
  25. ↑ "LianBio Announces Marketing Approval of Camzyos (mavacamten) in the Macau Special Administrative Region (SAR) of China" (Press release). LianBio. 11 May 2023. Retrieved 28 June 2023– via GlobeNewswire.
  26. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl: 10665/330961 .

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.